Official Title

Lidocaine For Neuroprotection During Cardiac Surgery
  • Phase

    N/A
  • Study Type

    Interventional
  • Intervention/Treatment

    lidocaine ...
  • Study Participants

    550
The purpose of this study is to see if a drug called lidocaine prevents cognitive injury (a decline in mental abilities) after heart surgery. Lidocaine is currently FDA approved and is commonly used for treating some heart rhythm disorders and for regional anesthesia (blocking nerves). The investigators are enrolling subjects in this research project to see if lidocaine will reduce the high incidence of cognitive injury seen after heart surgery. As part of this study, the investigators will also evaluate the relationship between cognitive injury and genetic makeup and the chemical changes in the subjects blood during and after surgery.
Study Started
Jul 31
2009
Primary Completion
Jul 18
2016
Study Completion
May 23
2017
Results Posted
Aug 24
2017
Last Update
May 10
2019

Drug Lidocaine

Lidocaine versus placebo infusion for 48 hours

Drug Placebo

Lidocaine versus placebo infusion for 48 hours

Lidocaine Experimental

Lidocaine infusion for 48 hours

Placebo Placebo Comparator

Normal saline infusion for 48 hours

Criteria

Inclusion Criteria:

CABG, CABG + Valve, or Valve surgery
Use of cardiopulmonary bypass

Exclusion Criteria:

Less than 50 years of age
History of diabetes
History of symptomatic cerebrovascular disease (e.g. prior stroke) with residual deficit
Alcoholism (> 2 drinks/day)
History of psychiatric illness (any clinical diagnoses requiring therapy)
History of drug abuse (any illicit drug use in the past 3 months)
Hepatic insufficiency (liver function tests > 1.5 times the upper limit of normal)
Severe pulmonary insufficiency (requiring home oxygen therapy)
Renal failure (baseline serum creatinine > 2.0 mg/dl)
Pregnant women
Unable to read and thus unable to complete the cognitive testing
Score < 24 on a baseline Mini Mental State examination (MMSE) or greater than or equal to 27 on the baseline Center for Epidemiological Studies Depression (CES-D) Scale -

Summary

Lidocaine

Placebo

All Events

Event Type Organ System Event Term Lidocaine Placebo

Change in Cognitive Function From Baseline Characterized as Continuous Cognitive Change

To characterize cognitive function over time, while minimizing potential redundancy in the cognitive measures, a factor analysis was performed on the 14 cognitive test scores from baseline. We chose a five-factor solution, which represents 5 cognitive domains: structured verbal memory, unstructured verbal memory, executive function, visual memory and attention/concentration. To quantify overall cognitive function, a baseline cognitive index was first calculated as the mean of the 5 preoperative domain scores. The cognitive index score has a mean of zero, thus any positive score is above the mean, any negative score is below the mean. A continuous change score was then calculated by subtracting the baseline from the 6-week cognitive index. The resulting outcome measure is unbounded with standard deviation of 0.35. A negative change score indicating decline and a positive score indicating improvement.

Lidocaine

0.07
units on a scale (Mean)
Standard Deviation: 0.32

Placebo

0.07
units on a scale (Mean)
Standard Deviation: 0.37

Count of Participants With a Decline of Greater Than or Equal to One Standard Deviation in One or More of Five Cognitive Domain Scores Reported as a Dichotomous Post-operative Cognitive Deficit (POCD) Outcome

To characterize cognitive function over time, while minimizing potential redundancy in the cognitive measures, a factor analysis was performed on the 14 cognitive test scores from baseline. We chose a five-factor solution, which represents 5 cognitive domains: structured verbal memory, unstructured verbal memory, executive function, visual memory and attention/concentration. Each domain score is normally distributed with a mean of zero. A change score was calculated for each domain by subtracting the baseline from the 6-week score. A dichotomous outcome variable of post-operative cognitive deficit was defined as a decline of ≥1 standard deviation in 1 or more of the 5 domains.

Lidocaine

Placebo

Transcerebral Activation Gradients of Platelets

Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removalime points and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups

Lidocaine

6 hours post cross-clamp removal

0.37
Mean linear fluorescence intensity-MLFI (Mean)
Standard Deviation: 2.65

Baseline

-0.03
Mean linear fluorescence intensity-MLFI (Mean)
Standard Deviation: 0.79

Cross-clamp removal

0.03
Mean linear fluorescence intensity-MLFI (Mean)
Standard Deviation: 1.21

End of Bypass

0.33
Mean linear fluorescence intensity-MLFI (Mean)
Standard Deviation: 3.25

Placebo

6 hours post cross-clamp removal

0.27
Mean linear fluorescence intensity-MLFI (Mean)
Standard Deviation: 1.07

Baseline

0.35
Mean linear fluorescence intensity-MLFI (Mean)
Standard Deviation: 1.91

Cross-clamp removal

0.43
Mean linear fluorescence intensity-MLFI (Mean)
Standard Deviation: 1.44

End of Bypass

0.05
Mean linear fluorescence intensity-MLFI (Mean)
Standard Deviation: 2.65

Transcerebral Activation Gradients of Neutrophils

Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removal and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups

Lidocaine

6 hours post cross-clamp removal

1.04
Mean linear fluorescence intensity-MLFI (Mean)
Standard Deviation: 7.08

Baseline

-2.02
Mean linear fluorescence intensity-MLFI (Mean)
Standard Deviation: 8.15

Cross-clamp removal

0.56
Mean linear fluorescence intensity-MLFI (Mean)
Standard Deviation: 6.82

End of Bypass

0.58
Mean linear fluorescence intensity-MLFI (Mean)
Standard Deviation: 4.54

Placebo

6 hours post cross-clamp removal

-0.68
Mean linear fluorescence intensity-MLFI (Mean)
Standard Deviation: 8.61

Baseline

-0.08
Mean linear fluorescence intensity-MLFI (Mean)
Standard Deviation: 9.17

Cross-clamp removal

0.17
Mean linear fluorescence intensity-MLFI (Mean)
Standard Deviation: 5.53

End of Bypass

1.19
Mean linear fluorescence intensity-MLFI (Mean)
Standard Deviation: 6.76

Transcerebral Activation Gradients of Monocytes

Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removalime points and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups

Lidocaine

6 hours post cross-clamp removal

1.21
Mean linear fluorescence intensity-MLFI (Mean)
Standard Deviation: 15.08

Baseline

-4.22
Mean linear fluorescence intensity-MLFI (Mean)
Standard Deviation: 19.10

Cross-clamp removal

-2.46
Mean linear fluorescence intensity-MLFI (Mean)
Standard Deviation: 16.94

End of Bypass

-0.34
Mean linear fluorescence intensity-MLFI (Mean)
Standard Deviation: 19.57

Placebo

6 hours post cross-clamp removal

0.54
Mean linear fluorescence intensity-MLFI (Mean)
Standard Deviation: 13.69

Baseline

-0.04
Mean linear fluorescence intensity-MLFI (Mean)
Standard Deviation: 17.78

Cross-clamp removal

1.83
Mean linear fluorescence intensity-MLFI (Mean)
Standard Deviation: 16.80

End of Bypass

2.64
Mean linear fluorescence intensity-MLFI (Mean)
Standard Deviation: 15.69

Transcerebral Activation Gradient of Platelet-neutrophil Conjugates

Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removalime points and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups

Lidocaine

6 hours post cross-clamp removal

-0.1
Mean linear fluorescence intensity-MLFI (Mean)
Standard Deviation: 5.40

Baseline

-0.15
Mean linear fluorescence intensity-MLFI (Mean)
Standard Deviation: 9.64

Cross-clamp removal

0.02
Mean linear fluorescence intensity-MLFI (Mean)
Standard Deviation: 4.33

End of Bypass

-0.73
Mean linear fluorescence intensity-MLFI (Mean)
Standard Deviation: 4.99

Placebo

6 hours post cross-clamp removal

0.19
Mean linear fluorescence intensity-MLFI (Mean)
Standard Deviation: 4.73

Baseline

-0.43
Mean linear fluorescence intensity-MLFI (Mean)
Standard Deviation: 8.40

Cross-clamp removal

-0.73
Mean linear fluorescence intensity-MLFI (Mean)
Standard Deviation: 3.97

End of Bypass

-0.4
Mean linear fluorescence intensity-MLFI (Mean)
Standard Deviation: 5.12

Change in Cognitive Function From Baseline

To characterize cognitive function over time, while minimizing potential redundancy in the cognitive measures, a factor analysis was performed on the 14 cognitive test scores from baseline. We chose a five-factor solution, which represents 5 cognitive domains: structured verbal memory, unstructured verbal memory, executive function, visual memory and attention/concentration. To quantify overall cognitive function, a baseline cognitive index was first calculated as the mean of the 5 preoperative domain scores. The cognitive index score has a mean of zero, thus any positive score is above the mean, any negative score is below the mean. A continuous change score was then calculated by subtracting the baseline from the 1 year cognitive index. The resulting outcome measure is unbounded with standard deviation of 0.35. A negative change score indicating decline and a positive score indicating improvement

Lidocaine

0.09
units on a scale (Mean)
Standard Deviation: 0.34

Placebo

0.07
units on a scale (Mean)
Standard Deviation: 0.34

Change in Center for Epidemiological Studies Depression Scale (CES-D)

Center for Epidemiological Studies Depression Scale (CES-D). The CES-D is a 20-item self-report examination designed to measure symptoms of depression. Subjects rate the degree to which they have experienced a range of symptoms of depression, such as "I had crying spells" and "I felt lonely." Scores range from 0 to 60, with higher scores indicating greater depressive symptoms. Scores greater than 16 are typically considered indicative of clinically significant depression.

Lidocaine

0.57
units on a scale (Mean)
Standard Deviation: 7.5

Placebo

0.16
units on a scale (Mean)
Standard Deviation: 8.3

Change in Duke Activity Status Index (DASI)

The DASI is a 12-item scale of functional capacity that has been found to correlate well with objective measures of maximal exercise capacity. Items reflect activities of personal care, ambulation, household tasks, sexual function, and recreational activities. Activities done "with no difficulty" receive scores, which are weighted and summed, for a quantitative measure of functional status. Scores range from 0 to 60; a higher-weighted score indicates better function.

Lidocaine

-10.98
units on a scale (Mean)
Standard Deviation: 15.4

Placebo

-11.67
units on a scale (Mean)
Standard Deviation: 16.8

Change in Center for Epidemiological Studies Depression Scale (CES-D)

Center for Epidemiological Studies Depression Scale (CES-D). The CES-D is a 20-item self-report examination designed to measure symptoms of depression. Subjects rate the degree to which they have experienced a range of symptoms of depression, such as "I had crying spells" and "I felt lonely." Scores range from 0 to 60, with higher scores indicating greater depressive symptoms. Scores greater than 16 are typically considered indicative of clinically significant depression.

Lidocaine

-1.27
units on a scale (Mean)
Standard Deviation: 7.7

Placebo

-0.89
units on a scale (Mean)
Standard Deviation: 7.9

Change in Duke Activity Status Index (DASI)

The DASI is a 12-item scale of functional capacity that has been found to correlate well with objective measures of maximal exercise capacity. Items reflect activities of personal care, ambulation, household tasks, sexual function, and recreational activities. Activities done "with no difficulty" receive scores, which are weighted and summed, for a quantitative measure of functional status. Scores range from 0 to 60; a higher-weighted score indicates better function.

Lidocaine

6.3
units on a scale (Mean)
Standard Deviation: 18.3

Placebo

6.96
units on a scale (Mean)
Standard Deviation: 16.9

Change in Neurological Function, as Measured by the National Institutes of Health Stroke Scale (NIHSS)

The National Institutes of Health Stroke Scale (NIHSS) is a 15-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. A trained observer rates the patent's ability to answer questions and perform activities. Ratings for each item are scored with 3 to 5 grades with 0 as normal, and there is an allowance for untestable items. The range of scores is from 0 (normal) to 42 (profound effect of stroke on patient).

Lidocaine

0.05
units on a scale (Mean)
Standard Deviation: 0.5

Placebo

0.04
units on a scale (Mean)
Standard Deviation: 0.5

Change in Neurological Function, as Measured by the National Institutes of Health Stroke Scale (NIHSS)

The National Institutes of Health Stroke Scale (NIHSS) is a 15-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. A trained observer rates the patent's ability to answer questions and perform activities. Ratings for each item are scored with 3 to 5 grades with 0 as normal, and there is an allowance for untestable items. The range of scores is from 0 (normal) to 42 (profound effect of stroke on patient).

Lidocaine

0.05
units on a scale (Mean)
Standard Deviation: 0.70

Placebo

0.07
units on a scale (Mean)
Standard Deviation: 0.60

Change in Spielberger State Anxiety Inventory (STAI)

Spielberger State Anxiety Inventory (STAI): The STAI consists of two 20-item scales that measure anxiety. Representative items include statements such as "I feel nervous" and "I feel worried." These items are rated on a 4-point scale, based on how well they describe the patient's current or typical mood, from "not at all" to "very much so." Scores range from 20 to 80, with higher scores indicating greater anxiety.

Lidocaine

-7.12
units on a scale (Mean)
Standard Deviation: 12.1

Placebo

-6.31
units on a scale (Mean)
Standard Deviation: 11.4

Change in Spielberger State Anxiety Inventory (STAI)

Spielberger State Anxiety Inventory (STAI): The STAI consists of two 20-item scales that measure anxiety. Representative items include statements such as "I feel nervous" and "I feel worried." These items are rated on a 4-point scale, based on how well they describe the patient's current or typical mood, from "not at all" to "very much so." Scores range from 20 to 80, with higher scores indicating greater anxiety.

Lidocaine

-6.7
units on a scale (Mean)
Standard Deviation: 12.7

Placebo

-6.39
units on a scale (Mean)
Standard Deviation: 10.3

Change in Symptom Limitations

Symptom limitations: Patients were given a list of eight symptoms and asked to rate the degree to which the symptom limited daily activities. The symptoms were angina, shortness of breath, arthritis, back trouble, leg pains, headaches, fatigue, and other. Scores range from 8 to 32, with higher scores indicating greater limitations.

Lidocaine

-0.67
units on a scale (Mean)
Standard Deviation: 4.0

Placebo

-0.8
units on a scale (Mean)
Standard Deviation: 3.9

Change in Symptom Limitations

Symptom limitations: Patients were given a list of eight symptoms and asked to rate the degree to which the symptom limited daily activities. The symptoms were angina, shortness of breath, arthritis, back trouble, leg pains, headaches, fatigue, and other. Scores range from 8 to 32, with higher scores indicating greater limitations.

Lidocaine

-1.39
units on a scale (Mean)
Standard Deviation: 3.8

Placebo

-1.48
units on a scale (Mean)
Standard Deviation: 3.8

Change in the Duke Older Americans Resources and Services Procedures- Instrumental Activities of Daily Living (OARS-IADL)

Duke Older Americans Resources and Services Procedures- Instrumental Activities of Daily Living (OARS-IADL): This measure contains six items that assess the ability to perform important tasks for daily living (e.g., "Could you prepare your own meals?" "Could you drive a car?"). Scores range from 6 to 24. Higher scores indicate increasing difficulty in engaging in daily activities.

Lidocaine

2.46
units on a scale (Mean)
Standard Deviation: 4.2

Placebo

2.1
units on a scale (Mean)
Standard Deviation: 3.9

Change in the Duke Older Americans Resources and Services Procedures- Instrumental Activities of Daily Living (OARS-IADL)

Duke Older Americans Resources and Services Procedures- Instrumental Activities of Daily Living (OARS-IADL): This measure contains six items that assess the ability to perform important tasks for daily living (e.g., "Could you prepare your own meals?" "Could you drive a car?"). Scores range from 6 to 24. Higher scores indicate increasing difficulty in engaging in daily activities.

Lidocaine

-0.15
units on a scale (Mean)
Standard Deviation: 2.1

Placebo

-0.31
units on a scale (Mean)
Standard Deviation: 2.6

Change in the Cognitive Difficulties Scale

Cognitive Difficulties Scale: a 39-item scale, is a self-report assessment of perceived problems in long- and short-term memory, concentration, attention, and psycho-motor coordination. Sample items are "I forget errands I planned to do" and "I fail to recognize people I know." Scores range from 39 to 164, with higher scores indicating greater cognitive difficulty.

Lidocaine

-3.0
units on a scale (Mean)
Standard Deviation: 14.6

Placebo

-3.21
units on a scale (Mean)
Standard Deviation: 15.9

Change in the Cognitive Difficulties Scale

Cognitive Difficulties Scale: a 39-item scale, is a self-report assessment of perceived problems in long- and short-term memory, concentration, attention, and psycho-motor coordination. Sample items are "I forget errands I planned to do" and "I fail to recognize people I know." Scores range from 39 to 164, with higher scores indicating greater cognitive difficulty.

Lidocaine

-0.46
units on a scale (Mean)
Standard Deviation: 16.1

Placebo

-1.02
units on a scale (Mean)
Standard Deviation: 17

Change in Perceived Social Support

Perceived Social Support Scale: Twelve items indicate how strongly subjects agree that there is "a special person who is around when I am in need" and "my family really tries to help me." Choices range from "very strongly disagree" to "very strongly agree." Items are summed for a range of 12 to 84, with a high score meaning more social support.

Lidocaine

1.23
units on a scale (Mean)
Standard Deviation: 14

Placebo

-0.49
units on a scale (Mean)
Standard Deviation: 13.9

Change in Perceived Social Support

Perceived Social Support Scale: Twelve items indicate how strongly subjects agree that there is "a special person who is around when I am in need" and "my family really tries to help me." Choices range from "very strongly disagree" to "very strongly agree." Items are summed for a range of 12 to 84, with a high score meaning more social support.

Lidocaine

0.71
units on a scale (Mean)
Standard Deviation: 13.4

Placebo

-1.16
units on a scale (Mean)
Standard Deviation: 12.9

Change in Social Activity

Social Activity: This measure consisted of eight items that indicate the degree of social interaction. Sample items are "How often do you talk on the telephone with friends and relatives?" and "How often do you attend meetings of social groups, clubs, or civic organizations?" Scores range from 8 to 32. A lower score indicates more social activity.

Lidocaine

0.95
units on a scale (Mean)
Standard Deviation: 3.4

Placebo

1.59
units on a scale (Mean)
Standard Deviation: 3.2

Change in Social Activity

Social Activity: This measure consisted of eight items that indicate the degree of social interaction. Sample items are "How often do you talk on the telephone with friends and relatives?" and "How often do you attend meetings of social groups, clubs, or civic organizations?" Scores range from 8 to 32. A lower score indicates more social activity.

Lidocaine

-0.2
units on a scale (Mean)
Standard Deviation: 3.2

Placebo

0.03
units on a scale (Mean)
Standard Deviation: 3.4

Change in Study 36-Item Short Form Health Survey (SF-36)

The Medical Outcomes Study 36-Item Short Form Health Survey (SF-36): The SF-36 was designed to measure general health status. Two scales were used: Work Activities (four items) and General Health (one item). For the work activities scale, the reported score was the sum of four questions, each with values ranging from 1 to 4, the total score could range from 4 to 16. A higher score on Work Activities indicates more health-related problems For the general health question, the patients ranked their health from Excellent (1) to poor (5), the scale ranged from 1 to 5 with 1 being best health and 5 being worst. A high score in General Health indicates poorer health state.

Lidocaine

6-Week Change General health perception

-0.004
units on a scale (Mean)
Standard Deviation: 1.3

6-Week Change Work activities

2.71
units on a scale (Mean)
Standard Deviation: 4.9

Placebo

6-Week Change General health perception

-0.03
units on a scale (Mean)
Standard Deviation: 1.2

6-Week Change Work activities

3.0
units on a scale (Mean)
Standard Deviation: 4.3

Change in Study 36-Item Short Form Health Survey (SF-36)

The Medical Outcomes Study 36-Item Short Form Health Survey (SF-36): The SF-36 was designed to measure general health status. Two scales were used: Work Activities (four items) and General Health (one item). For the work activities scale, the reported score was the sum of four questions, each with values ranging from 1 to 4, the total score could range from 4 to 16. A higher score on Work Activities indicates more health-related problems For the general health question, the patients ranked their health from Excellent (1) to poor (5), the scale ranged from 1 to 5 with 1 being best health and 5 being worst. A high score in General Health indicates poorer health state.

Lidocaine

1 year Change General health perception

-0.28
units on a scale (Mean)
Standard Deviation: 1.2

1 year Change Work Activities

-1.37
units on a scale (Mean)
Standard Deviation: 4.3

Placebo

1 year Change General health perception

-0.43
units on a scale (Mean)
Standard Deviation: 1.1

1 year Change Work Activities

-1.42
units on a scale (Mean)
Standard Deviation: 4.1

Change in Neurological Function, as Measured by the Western Perioperative Neurologic Scale (WPNS)

The Western perioperative neurologic scale was designed to detect neurologic deficits after cardiac surgery. It includes 14 items classified into eight domains (mentation, speech, cranial nerve function, motor weakness, sensation and cerebellum, reflexes, and gait). Each item is scored from 0 (severe deficit) to3 (normal), and a maximum score of 42 indicates normal neurological function.

Lidocaine

0.04
units on a scale (Mean)
Standard Deviation: 1.10

Placebo

-0.01
units on a scale (Mean)
Standard Deviation: 1.3

Change in Neurological Function, as Measured by the Western Perioperative Neurologic Scale (WPNS)

The Western perioperative neurologic scale was designed to detect neurologic deficits after cardiac surgery. It includes 14 items classified into eight domains (mentation, speech, cranial nerve function, motor weakness, sensation and cerebellum, reflexes, and gait). Each item is scored from 0 (severe deficit) to3 (normal), and a maximum score of 42 indicates normal neurological function.

Lidocaine

0.02
units on a scale (Mean)
Standard Deviation: 1.10

Placebo

-0.02
units on a scale (Mean)
Standard Deviation: 1.20

Total

420
Participants

Age, Continuous

66.7
years (Mean)
Standard Deviation: 9.3

Region of Enrollment

Sex: Female, Male

Overall Study

Lidocaine

Placebo

Drop/Withdrawal Reasons

Lidocaine

Placebo